Preethi Krishnan, Ph.D. - Publications

2000 University of North Carolina, Chapel Hill, Chapel Hill, NC 

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Analysis of HCV Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir/Ritonavir and Ombitasvir. Antimicrobial Agents and Chemotherapy. PMID 26643326 DOI: 10.1128/AAC.02606-15  1
2015 Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrobial Agents and Chemotherapy. PMID 26282418 DOI: 10.1128/AAC.01229-15  1
2015 Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. Resistance Analysis of Baseline and Treatment-Emergent Variants in the AVIATOR Study With Paritaprevir/r, Ombitasvir and Dasabuvir in HCV Genotype 1. Antimicrobial Agents and Chemotherapy. PMID 26100711 DOI: 10.1128/AAC.00998-15  1
2015 Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrobial Agents and Chemotherapy. 59: 1505-11. PMID 25534735 DOI: 10.1128/AAC.04619-14  1
2015 Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrobial Agents and Chemotherapy. 59: 979-87. PMID 25451055 DOI: 10.1128/AAC.04226-14  1
2014 DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. Journal of Medicinal Chemistry. 57: 2047-57. PMID 24400777 DOI: 10.1021/jm401398x  1
2013 DeGoey DA, Betebenner DA, Grampovnik DJ, Liu D, Pratt JK, Tufano MD, He W, Krishnan P, Pilot-Matias TJ, Marsh KC, Molla A, Kempf DJ, Maring CJ. Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A. Bioorganic & Medicinal Chemistry Letters. 23: 3627-30. PMID 23642966 DOI: 10.1016/j.bmcl.2013.04.009  1
2012 Peters-Libeu C, Miller J, Rutenber E, Newhouse Y, Krishnan P, Cheung K, Hatters D, Brooks E, Widjaja K, Tran T, Mitra S, Arrasate M, Mosquera LA, Taylor D, Weisgraber KH, et al. Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure. Journal of Molecular Biology. 421: 587-600. PMID 22306738 DOI: 10.1016/j.jmb.2012.01.034  1
2011 Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nature Chemical Biology. 7: 925-34. PMID 22037470 DOI: 10.1038/nchembio.694  1
2008 He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrobial Agents and Chemotherapy. 52: 1101-10. PMID 18086851 DOI: 10.1128/AAC.01149-07  1
2007 Tripathi RL, Krishnan P, He Y, Middleton T, Pilot-Matias T, Chen CM, Lau DT, Lemon SM, Mo H, Kati W, Molla A. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Research. 73: 40-9. PMID 16914212 DOI: 10.1016/j.antiviral.2006.07.005  1
2005 Peters-Libeu C, Newhouse Y, Krishnan P, Cheung K, Brooks E, Weisgraber K, Finkbeiner S. Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications. 61: 1065-8. PMID 16511236 DOI: 10.1107/S1744309105036547  1
2001 Krishnan P, Bastow KF. Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaphthoquinone derivatives alpha-lapachone and beta-lapachone. Cancer Chemotherapy and Pharmacology. 47: 187-98. PMID 11320661 DOI: 10.1007/s002800000221  1
2000 Krishnan P, Bastow KF. The 9-position in berberine analogs is an important determinant of DNA topoisomerase II inhibition. Anti-Cancer Drug Design. 15: 255-64. PMID 11200501  1
2000 Krishnan P, Bastow KF. Novel mechanisms of DNA topoisomerase II inhibition by pyranonaphthoquinone derivatives-eleutherin, alpha lapachone, and beta lapachone. Biochemical Pharmacology. 60: 1367-79. PMID 11008131 DOI: 10.1016/S0006-2952(00)00437-8  1
2000 Tachibana Y, Zhu XK, Krishnan P, Lee KH, Bastow KF. Characterization of human lung cancer cells resistant to 4'-O-demethyl-4beta-(2"-nitro-4"-fluoroanilino)-4-desoxypodophyllotoxin , a unique compound in the epipodophyllotoxin antitumor class. Anti-Cancer Drugs. 11: 19-28. PMID 10757559 DOI: 10.1097/00001813-200001000-00004  1
Show low-probability matches.